Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature

Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature

Introduction: Anti-PD1 agents are widely used in the treatment of solid tumors. This has prompted the recognition of a class of immune-related adverse events (irAEs), due to the activation of autoimmune T-cells. Pembrolizumab is an anti-PD1 agent, which has been related to an increased risk of vario...

Full description

Bibliographic Details
Main Authors:	Francesco Bruno, Rosa Antonietta Palmiero, Bruno Ferrero, Federica Franchino, Alessia Pellerino, Enrica Milanesi, Riccardo Soffietti, Roberta Rudà
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-05-01
Series:	Frontiers in Neurology
Subjects:	pembrolizumab anti-PD1 agents neurological immune-related adverse effects immune-related neurological complications autoimmune neuropathy case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2021.669493/full

Similar Items

Pembrolizumab related Guillain barre syndrome, a rare presentation in a patient with a history of lupus and bladder cancer
by: Vikram Sangani, et al.
Published: (2021-05-01)

Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab
by: Salma Charabi, et al.
Published: (2021-04-01)

A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab
by: Jaqueline Ghosn, et al.
Published: (2018-10-01)

Immune Checkpoint Inhibitor-Induced Gastroduodenitis: Recurrence after Rechallenge with Pembrolizumab
by: Catarina O’Neill, et al.
Published: (2021-04-01)

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
by: Fanny Zulay Acero Brand, et al.
Published: (2018-03-01)

Pembrolizumab on pre-existing inclusion body myositis: a case report
by: Naohiro Uchio, et al.
Published: (2020-09-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
by: Bylicki O, et al.
Published: (2018-07-01)

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
by: du Rusquec P, et al.
Published: (2019-05-01)

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
by: Maria Anna Siciliano, et al.
Published: (2020-10-01)

Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis
by: Mike Nguyen, et al.
Published: (2019-09-01)

Severe gastritis due to pembrolizumab treatment in a lung cancer patient
by: Noriko Hayama, et al.
Published: (2020-10-01)

Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection
by: Cheng Zhou, et al.
Published: (2019-02-01)

Very Delayed Acute Hepatitis after Pembrolizumab Therapy for Advanced Malignancy: How Long Should We Watch?
by: Timothy Phan, et al.
Published: (2021-02-01)

Case report: reinitiating pembrolizumab treatment after small bowel perforation
by: Tim N. Beck, et al.
Published: (2019-04-01)

Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report
by: Chia-Yi Tian, et al.
Published: (2021-04-01)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
by: Abdulaali R. Almutairi, et al.
Published: (2020-02-01)

Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma
by: Nikolaos Spathas, et al.
Published: (2018-09-01)

Cryptogenic Polyneuropathy : Clinical, Environmental, And Genetic Studies
by: Lindh, Jonas
Published: (2011)

Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung
by: Xiaohong Xie, et al.
Published: (2021-01-01)

Durable complete remission after Pembrolizumab in pretreated advanced endometrial cancer: A case report
by: Bacigalupo, L., et al.
Published: (2022)

Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
by: Ine Lambert, et al.
Published: (2021-06-01)

A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer
by: Kyung Woo Kim, et al.
Published: (2021-06-01)

Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer
by: Stephanie Andrews, et al.
Published: (2020-12-01)

Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone
by: Samuel Rosner, et al.
Published: (2017-04-01)

Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review
by: Alessandro Cafaro, et al.
Published: (2020-08-01)

Pembrolizumab-Induced Delayed-Onset Hepatitis
by: Kensuke Kanaoka, et al.
Published: (2020-11-01)

Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report
by: Li Shen, et al.
Published: (2021-04-01)

Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma
by: Michelle A. McNally, BSN, et al.
Published: (2021-04-01)

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
by: Neta Tsur, et al.
Published: (2019-10-01)

Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset
by: Shuntaro Aoki, et al.
Published: (2020-12-01)

A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency
by: Kei Sonehara, et al.
Published: (2021-01-01)

Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer
by: Shinya Asatani, et al.
Published: (2021-06-01)

The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
by: Ke Ma, et al.
Published: (2018-12-01)

The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials
by: Siyao Deng, et al.
Published: (2019-09-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2017-06-01)

Case Report: SAPHO Syndrome Mimicking Bone Metastases During Treatment With Pembrolizumab for Non-small Cell Lung Cancer
by: Yuko Kubo, et al.
Published: (2021-07-01)

Challenging the standard of care in advanced melanoma: focus on pembrolizumab
by: Abdul-Karim RM, et al.
Published: (2017-09-01)

Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report
by: Hikaru Kamo, et al.
Published: (2019-08-01)

Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy – Interrupt or Continue Treatment – The Role of Immunohistochemical Examination
by: Bożena Cybulska-Stopa, et al.
Published: (2019-10-01)